Home » Stocks » SAVA

Cassava Sciences, Inc. (SAVA)

Stock Price: $7.76 USD 0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed
Pre-market: $7.50 -0.26 (-3.35%) Nov 30, 6:17 AM

Stock Price Chart

Key Info

Market Cap 198.49M
Revenue (ttm) n/a
Net Income (ttm) -5.23M
Shares Out 25.58M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE 34.01
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $7.76
Previous Close $7.76
Change ($) 0.00
Change (%) 0.00%
Day's Open 7.93
Day's Range 7.60 - 7.94
Day's Volume 1,645,209
52-Week Range 1.65 - 12.25

More Stats

Market Cap 198.49M
Enterprise Value 174.73M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 25.58M
Float n/a
EPS (basic) -0.25
EPS (diluted) -0.23
FCF / Share -0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.99M
Short Ratio 1.41
Short % of Float n/a
Beta 1.89
PE Ratio n/a
Forward PE 34.01
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 10.57
Revenue n/a
Operating Income -5.40M
Net Income -5.23M
Free Cash Flow -4.44M
Net Cash 23.76M
Net Cash / Share 0.93
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -16.40%
ROE -25.26%
ROIC 975.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$19.33*
(149.10% upside)
Low
14.0
Current: $7.76
High
24.0
Target: 19.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue------41.1210.8911.4816.81
Revenue Growth------277.58%-5.17%-31.68%-
Gross Profit------41.1210.8911.4816.81
Operating Income-4.96-6.66-11.95-14.96-14.20-12.4331.37-3.90-3.51-13.70
Net Income-4.63-6.56-11.91-14.85-14.15-12.3931.54-3.45-2.61-12.02
Shares Outstanding17.4110.686.546.526.486.476.436.396.316.09
Earnings Per Share-0.27-0.61-1.82-2.28-2.17-1.894.90-0.56-0.42-1.96
Dividend Per Share-------5.25-14.00
Operating Cash Flow-2.51-4.77-8.24-12.23-9.05-9.55-6.95-7.17-0.26-0.14
Capital Expenditures-0.02---0.08-0.20-0.08----
Free Cash Flow-2.53-4.77-8.24-12.31-9.25-9.63-6.95-7.17-0.26-0.14
Cash & Equivalents23.0819.8110.4818.7131.3040.5949.8456.2598.1391.23
Total Debt0.09---------
Net Cash / Debt22.9919.8110.4818.7131.3040.5949.8456.2598.1391.23
Assets23.4920.1410.8319.3031.9240.9150.1056.8698.9699.20
Liabilities1.390.511.130.672.550.851.8043.7254.5766.26
Book Value22.1019.639.7018.6429.3740.0648.3013.1444.3932.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cassava Sciences, Inc.
Country United States
Employees 9
CEO Remi Barbier

Stock Information

Ticker Symbol SAVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SAVA

Description

Cassava Sciences, a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.